Active, Not Recruiting
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata - IM011-134
Updated: 27 březen, 2024 | ClinicalTrials.gov
Fáze
Pohlaví
Věková skupina
Active, Not Recruiting
Inclusion Criteria: - Documented clinical diagnosis of Alopecia Areata (AA) for at least 6 months. - Current episode of scalp hair loss (at screening) must meet the following criteria: duration at least 6 months; duration of current hair loss episode of AA affecting ≥ 50% of the scalp not exceeding 8 years; scalp hair loss has been stable (no significant spontaneous regrowth [> 10%] over the last 6 months) - SALT score ≥ 50 at Screening and Day 1. Participant with complete scalp hair loss (SALT score of 100) with or without body hair involvement can be included. Exclusion Criteria: - Participant with diffuse-type AA or other forms of hair loss, including traction alopecia, lichen planopilaris, central centrifugal cicatricial alopecia, frontal fibrosing alopecia, etc. - Other active skin diseases affecting the scalp that in the opinion of the investigator may interfere with accurate assessment of SALT score. - Extensive tattooing of the scalp that, in the opinion of the investigator, may interfere with the accurate assessment of SALT score. Other protocol-defined inclusion/exclusion criteria apply.
Důrazně doporučujeme kontaktovat BMS a oznámit vedlejší účinky / nežádoucí příhody
Zde jsou definovány vedlejší účinky / nežádoucí příhody a další příhody, které by měly být hlášeny
Nahlásit vedlejší účinky / nežádoucí příhody nebo stížnosti na kvalitu produktu: lékařské informace
